Toggle Nav

Alogliptin (SYR-322)

Catalog No.
DPP-4 inhibitor,potent and highly selective
Grouped product items
SizePriceStock Qty
Evaluation Sample
In stock
In stock
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Alogliptin (also known as SYR-322), is a novel, orally-available and highly selective quinazolinone-based inhibitor of dipeptidyl peptidase-4 (DPP-4), a serine aminopeptidase catalyzing the cleavage of peptides, that potently inhibits human DPP-4 in vitro with 50% inhibition concentration IC50 value of 6.9 nM and barely exhibits any inhibition towards the closely related serine proteases, including DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidas and tryptase (IC50 > 100,000 nM for all). Alogliptin prevents DPP-4-catalyzed degradation of GLP-1 and GIP, which regulate concentrations of blood glucose by stimulating glucose-dependent insulin secretion, and hence is being investigated in the treatment of type 2 diabetes.


Bumsup Lee, Lihong Shi, Daniel B. Kassel, Tomoko Asakawa, Koji Takeuchi and Ronald J. Christopher. Pharmacokinetic, pharmacodynamics, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European Journal of Pharmacology 589 (2008) 306-314

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
Cas No.850649-61-5
Solubility≥14.75 mg/mL in DMSO, ≥100 mg/mL in EtOH with ultrasonic,insoluble in H2O
Chemical Name2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
SDFDownload SDF
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.


Cell experiment: [1]

Cell lines

U937 histiocyte

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

5 nM, 48h, inhibited cell proliferation 1 nM, 48h, inhibited MMP-1 secretion


Alogliptin inhibited cell proliferation by 53% at concentration of 5 nM. At 1 nM, alogliptin inhibited MMP-1 secretion significantly, suggesting that the inhibitory effect of alogliptin on MMP is not associated with that on cell proliferation.

Animal experiment : [2]

Animal models

Zucker fa/fa rats

Dosage form

Eight-week-old male Zucker fa/fa rats were divided into 5 groups based on body weight and fasting plasma glucose levels and administered vehicle alone (0.5% carboxymethylcellulose) or alogliptin at 0.3, 1, 3, or 10 mg/kg by single bolus oral gavage (5 ml/kg dose volume). At 30 min postdose, rats were given a glucose solution (1 g/kg, 2ml/kg dose volume). Blood glucose concentrations were analyzed up to 90min after glucose load using the Accu-Chek glucometer and plasma insulin concentrations were analyzed up to 60 min after glucose load using an insulin ELISA kit.


Early-phase insulin secretion was increased after a single dose of alogliptin compared with vehicle alone. Alogliptin increased about 1.5, 1.5, and 1.8 fold for the 0.3, 1, and 3 mg/kg doses. Significant decreases in blood glucose excursion were observed for all alogliptin doses compared with vehicle alone after an oral glucose load. Mean baseline-adjusted blood glucose AUC0–90 min was decreased by approximately 31%, 37%, and 41% for the 0.3, 1, and 3 mg/kg doses, respectively.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Ta N N, Li Y, Schuyler C A, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis, 2010, 213(2): 429-435.

[2] Lee B, Shi L, Kassel D B, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European journal of pharmacology, 2008, 589(1): 306-314.

Biological Activity

Description Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Targets DPP-4          
IC50 < 10 nM          

Quality Control

Chemical structure

Alogliptin (SYR-322)

Related Biological Data

Alogliptin (SYR-322)

Related Biological Data

Alogliptin (SYR-322)